Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients

(E-pub Ahead of Print)

Author(s): Mostafa Mohammadi*

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders


Become EABM
Become Reviewer
Call for Editor

Abstract:

This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.

Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.

The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php

BENTHAM SCIENCE DISCLAIMER:

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

free to download

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 29 January, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1871527320666210129121701

Article Metrics

PDF: 241